HLB's liver cancer drug clears key FDA hurdle for re-application

HLB's long-developed liver cancer drug, Rivoceranib, has cleared a crucial initial step in its renewed pursuit of U.S. Food and Drug Administration (FDA) approval. The path forward became clearer after the raw material production facility, managed by HLB's Chinese partner Hengrui Medicine, received a Voluntary Action Indicated (VAI) classification during a recent FDA inspection.

The VAI designation is a positive sign for HLB, indicating that while the FDA identified areas needing improvement at the manufacturing site, these issues do not warrant immediate regulatory enforcement actions. This outcome is a significant development for HLB, which has invested over two decades in the development of Rivoceranib.

This marks HLB's third attempt to gain FDA approval for the drug. The company has faced previous setbacks, making the VAI rating a critical milestone. The classification suggests that the facility meets general standards, with the identified issues being manageable and not posing an immediate risk to drug safety or efficacy.

With this hurdle cleared, HLB can now proceed with its application, hoping to overcome previous challenges and secure approval for Rivoceranib. The company's persistence underscores the potential of the drug in treating liver cancer, a disease with significant unmet medical needs.